Zydus Lifesciences, MSN Launch First Generic Adempas® (Riociguat Tablets) In US
Mumbai: Zydus Lifesciences Limited , in partnership with MSN Laboratories Private Limited, announced on October 5, 2026, the launch of Riociguat Tablets in the United States. The tablets are available in 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg strengths. Market Launch Zydus and MSN are the first companies to introduce a generic version of Adempas® (riociguat) in the US market . The product was…
Zydus Lifesciences, in collaboration with MSN Laboratories, has introduced the first generic version of Adempas® (riociguat tablets) in the United States on October 5, 2026. The tablets come in five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg. Zydus and MSN Laboratories are the exclusive companies to provide this generic alternative in the U.S. market.
MSN Laboratories, the manufacturer, developed and produced the Riociguat Tablets. Zydus Lifesciences USA Office conducted a USFDA inspection and received no observations, indicating regulatory approval. The USFDA has granted approval for Riociguat Tablets as a generic equivalent of Adempas® across all five strengths.
Riociguat Tablets are prescribed to treat adults with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Sharvil Patel, Managing Director of Zydus Lifesciences Limited, announced this milestone as the first generic riociguat in the U.S. market. He highlighted that it showcases the strength of their complex-generics pipeline and their capability for day-one launches in specialty categories.
MSN Reddy, Founder and CMD of MSN Laboratories, emphasized that the generic riociguat development requires a highly specialized molecule. The launch represents the depth of MSN's integrated API and formulation research and development (R&D) and the scale of their manufacturing capabilities.
The launch of generic riociguat aims to offer a more affordable option for U.S. patients suffering from pulmonary arterial hypertension and CTEPH. According to Bayer's Annual Report 2025, global sales of Adempas® reached approximately EUR 745 million (about USD 850 million) in 2025. This announcement is for informational purposes only and investors are advised to assess associated risks before making decisions.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.